Cosmo Pharmaceuticals N.V Asset Resilience Ratio
Cosmo Pharmaceuticals N.V asset resilience ratio. Cosmo Pharmaceuticals N.V (C43) has an Asset Resilience Ratio of 10.92% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Cosmo Pharmaceuticals N.V to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Cosmo Pharmaceuticals N.V (2016–2025)
Asset resilience ratio of Cosmo Pharmaceuticals N.V from 2016 to 2025. This chart shows how Cosmo Pharmaceuticals N.V's Asset Resilience Ratio has changed over time. Read Cosmo Pharmaceuticals N.V (C43) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Cosmo Pharmaceuticals N.V's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Cosmo Pharmaceuticals N.V balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €66.89 Million | 10.92% |
| Total Liquid Assets | €66.89 Million | 10.92% |
Asset Resilience Insights
- Moderate Liquidity: Cosmo Pharmaceuticals N.V has 10.92% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Cosmo Pharmaceuticals N.V Industry Peers by Asset Resilience Ratio
Compare Cosmo Pharmaceuticals N.V's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 0.08% |
|
Virbac SA
PA:VIRP |
Drug Manufacturers - General | 0.23% |
|
AstraZeneca PLC
LSE:AZN |
Drug Manufacturers - General | 0.06% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771 |
Drug Manufacturers - General | 1.97% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 6.46% |
Cosmo Pharmaceuticals N.V Asset Resilience Ratio by Year (2016–2025)
Cosmo Pharmaceuticals N.V asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Cosmo Pharmaceuticals N.V.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 10.92% | €66.89 Million ≈ $78.21 Million |
€612.64 Million ≈ $716.24 Million |
-4.34pp |
| 2024-12-31 | 15.26% | €98.67 Million ≈ $115.35 Million |
€646.77 Million ≈ $756.14 Million |
+8.00pp |
| 2022-12-31 | 7.26% | €55.13 Million ≈ $64.45 Million |
€759.59 Million ≈ $888.04 Million |
+4.32pp |
| 2021-12-31 | 2.94% | €23.65 Million ≈ $27.65 Million |
€805.56 Million ≈ $941.79 Million |
-1.58pp |
| 2020-12-31 | 4.51% | €26.91 Million ≈ $31.47 Million |
€596.16 Million ≈ $696.97 Million |
-22.46pp |
| 2019-12-31 | 26.97% | €157.82 Million ≈ $184.51 Million |
€585.16 Million ≈ $684.11 Million |
+4.80pp |
| 2018-12-31 | 22.18% | €138.75 Million ≈ $162.21 Million |
€625.69 Million ≈ $731.49 Million |
+16.60pp |
| 2017-12-31 | 5.57% | €27.76 Million ≈ $32.45 Million |
€497.97 Million ≈ $582.18 Million |
-5.44pp |
| 2016-12-31 | 11.01% | €48.84 Million ≈ $57.09 Million |
€443.47 Million ≈ $518.47 Million |
-- |
About Cosmo Pharmaceuticals N.V
Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant… Read more